Vaccibody AS is pleased to announce that it has received the approval from the regulatory authorities (Paul Ehrlich Institute), of its clinical trial application for VB10.16 immunotherapy, the company’s lead drug candidate for the treatment high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human...

The board of Vaccibody is pleased to announce Dr. Martin Bonde as the new CEO of the company from August 10th, 2015.
Dr. Bonde has more than 25 years of international experience from the biotech industry. He started his career in Dako AS, followed by Ostemeter AS...

Vaccibody AS is pleased to announce initiation of a new 4 year collaborative research project with the aim to improve animal production and health through development of improved vaccination strategies. The SAPHIR project brings together interdisciplinary expertise from 14 academic institutions, 5 small and medium-sized...

The research collaboration “New Targeting Vaccines for Sustainable Aquaculture” has received a grant of NOK 10 Million through the Norwegian Research Council’s program Biotek2021. Vaccibody is a partner in the project together with The Norwegian Veterinary Institute, Pharmaq AS, Kjeller Innovasjon and Kongla AS. The...

Vaccibody AS, a biopharmaceutical company focusing on immunotherapy and vaccines, is pleased to announce the filing of a CTA to initiate the first in man clinical study of its lead drug candidate VB10.16. The CTA was filed with the Paul Ehrlich Institute, the Federal German...

Vaccibody is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The Company’s proprietary vaccine platform increases the antibody and T-cell responses leading to remarkably effective vaccines. Vaccibody plans to initiate its first clinical trial with a...

Vaccibody AS is pleased to announce that the U.S. Patent Office has Issued patent No. US 8,932,603 B2 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell...

Vaccibody AS today announces that the European Patent Office (EPO) has granted European patent No. 1599504 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell responses.
This patent...

As Vaccibody is entering into a new development phase, the Board of Directors has initiated a search process for a new CEO with experience from clinical development and strategic partnering. On this background, Ole Henrik Brekke, CEO since 2006, has decided to leave the...